BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37097390)

  • 1. Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells.
    Sturm MJ; Henao-Restrepo JA; Becker S; Proquitté H; Beck JF; Sonnemann J
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8605-8617. PubMed ID: 37097390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells.
    Kerschner-Morales SL; Kühne M; Becker S; Beck JF; Sonnemann J
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2871-2883. PubMed ID: 32770382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative treatment effectiveness of ATR and HSP90 inhibition in Ewing's sarcoma cells.
    Marx C; Schaarschmidt MU; Kirkpatrick J; Marx-Blümel L; Halilovic M; Westermann M; Hoelzer D; Meyer FB; Geng Y; Buder K; Schadwinkel HM; Siniuk K; Becker S; Thierbach R; Beck JF; Sonnemann J; Wang ZQ
    Cell Biosci; 2021 Mar; 11(1):57. PubMed ID: 33743824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.
    Sonnemann J; Grauel D; Blümel L; Hentschel J; Marx C; Blumrich A; Focke K; Becker S; Wittig S; Schinkel S; Krämer OH; Beck JF
    Eur J Cancer; 2015 May; 51(7):841-51. PubMed ID: 25801700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
    Sonnemann J; Dreyer L; Hartwig M; Palani CD; Hong le TT; Klier U; Bröker B; Völker U; Beck JF
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):847-58. PubMed ID: 17486365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing's sarcoma cell line.
    Marx C; Marx-Blümel L; Lindig N; Thierbach R; Hoelzer D; Becker S; Wittig S; Lehmann R; Slevogt H; Heinzel T; Wang ZQ; Beck JF; Sonnemann J
    Invest New Drugs; 2018 Jun; 36(3):396-406. PubMed ID: 29150734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.
    Sonnemann J; Palani CD; Wittig S; Becker S; Eichhorn F; Voigt A; Beck JF
    Eur J Cancer; 2011 Jun; 47(9):1432-41. PubMed ID: 21334198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
    Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
    J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing's sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity.
    Sonnemann J; Kahl M; Siranjeevi PM; Blumrich A; Blümel L; Becker S; Wittig S; Winkler R; Krämer OH; Beck JF
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):17-26. PubMed ID: 26055805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
    Winter GE; Rix U; Lissat A; Stukalov A; Müllner MK; Bennett KL; Colinge J; Nijman SM; Kubicek S; Kovar H; Kontny U; Superti-Furga G
    Mol Cancer Ther; 2011 Oct; 10(10):1846-56. PubMed ID: 21768330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
    Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
    Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor.
    Knowles HJ; Schaefer KL; Dirksen U; Athanasou NA
    BMC Cancer; 2010 Jul; 10():372. PubMed ID: 20637078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
    Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.
    Guan H; Zhou Z; Gallick GE; Jia SF; Morales J; Sood AK; Corey SJ; Kleinerman ES
    Mol Cancer Ther; 2008 Jul; 7(7):1807-16. PubMed ID: 18644993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
    Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
    Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS; Woo CW; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.
    Lissat A; Vraetz T; Tsokos M; Klein R; Braun M; Koutelia N; Fisch P; Romero ME; Long L; Noellke P; Mackall CL; Niemeyer CM; Kontny U
    Am J Pathol; 2007 Jun; 170(6):1917-30. PubMed ID: 17525260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EWS Knockdown and Taxifolin Treatment Induced Differentiation and Removed DNA Methylation from p53 Promoter to Promote Expression of Puma and Noxa for Apoptosis in Ewing's Sarcoma.
    Hossain MM; Ray SK
    J Cancer Ther; 2014 Oct; 5(12):1092-1113. PubMed ID: 27547487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.
    Andreou D; Ranft A; Gosheger G; Timmermann B; Ladenstein R; Hartmann W; Bauer S; Baumhoer D; van den Berg H; Dijkstra PDS; Dürr HR; Gelderblom H; Hardes J; Hjorth L; Kreyer J; Kruseova J; Leithner A; Scobioala S; Streitbürger A; Tunn PU; Wardelmann E; Windhager R; Jürgens H; Dirksen U;
    Clin Orthop Relat Res; 2020 Feb; 478(2):290-302. PubMed ID: 31580267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.